MCID: ANL011
MIFTS: 27

Anal Canal Carcinoma malady

Cancer diseases, Endocrine diseases categories

Aliases & Classifications for Anal Canal Carcinoma

About this section

Aliases & Descriptions for Anal Canal Carcinoma:

Name: Anal Canal Carcinoma 10 11 12
Carcinoma of Anal Canal 10 65
 
Anal Canal Cancer 10 12
Anal Canal and Perianal Gland Carcinoma 10


Classifications:



External Ids:

Disease Ontology10 DOID:6126, DOID:0050688
NCIt42 C7489
SNOMED-CT59 285310000
ICD1027 C21.1

Summaries for Anal Canal Carcinoma

About this section
Disease Ontology:10 An anal canal cancer that derives from epithelial cells.

MalaCards based summary: Anal Canal Carcinoma, also known as carcinoma of anal canal, is related to anus disease and anal carcinoma in situ. An important gene associated with Anal Canal Carcinoma is NME1 (NME/NM23 Nucleoside Diphosphate Kinase 1). Affiliated tissues include prostate and skin.

Related Diseases for Anal Canal Carcinoma

About this section

Diseases related to Anal Canal Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 48)
idRelated DiseaseScoreTop Affiliating Genes
1anus disease30.5CD6, SLC14A2
2anal carcinoma in situ10.3
3colorectal cancer10.3
4colorectal cancer 1210.3
5anus cancer10.3
6gastrointestinal system cancer10.3
7hemorrhoid10.3
8intestinal benign neoplasm10.3
9intestinal disease10.3
10rectal disease10.3
11rectal neoplasm10.3
12anal canal squamous cell carcinoma10.2
13burns10.2
14leukemia10.2
15adenocarcinoma10.2
16prostate adenocarcinoma10.2
17prostatitis10.2
18prostate cancer10.2
19cervical cancer, somatic10.2
20colorectal cancer 210.2
21colorectal cancer 310.2
22colorectal cancer 1010.2
23colorectal cancer 1110.2
24tongue squamous cell carcinoma10.2
25vulvovaginal candidiasis10.2
26anal gland neoplasm10.2
27gastrointestinal carcinoma10.2
28anal canal adenocarcinoma10.2
29anal squamous cell carcinoma10.2
30female reproductive organ cancer10.2
31female reproductive system disease10.2
32kidney cancer10.2
33lymph node cancer10.2
34lymph node disease10.2
35prostate disease10.2
36reproductive system disease10.2
37uterine disease10.2
38malignant peripheral nerve sheath tumor10.0KRT20, NME1
39papillary follicular thyroid adenocarcinoma10.0KRT13, KRT20
40iridocyclitis10.0KRT13, KRT20
41bile duct mucoepidermoid carcinoma9.9KRT13, KRT20
42ovary sarcoma9.9KRT20, NME1
43vulva squamous cell carcinoma9.9KRT13, KRT20
44trichostrongyloidiasis9.9KRT13, KRT20
45parachordoma9.9KRT13, KRT20
46rectum sarcoma9.8CD6, KRT20, SLC14A2
47rectum adenocarcinoma9.8KRT20, SLC14A2
48gliomatosis cerebri9.0CD6, KRT13, KRT20, NME1, SLC14A2, SLC5A7

Graphical network of the top 20 diseases related to Anal Canal Carcinoma:



Diseases related to anal canal carcinoma

Symptoms for Anal Canal Carcinoma

About this section

Drugs & Therapeutics for Anal Canal Carcinoma

About this section

Drugs for Anal Canal Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 32)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Oxaliplatinapproved, investigationalPhase 4, Phase 2, Phase 1127661825-94-35310940, 9887054, 6857599, 43805, 6857599, 9887054
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
 
Oxalatoplatin
Oxalatoplatinum
Oxaliplatin
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
Oxaliplatino [Spanish]
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
oxaliplatin
2ColaNutraceuticalPhase 4, Phase 3, Phase 2, Phase 11690
3
Fentanylapproved, illicit, investigationalPhase 3649437-38-73345
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Abstral
Actiq
BIDD:GT0555
BRN 0494484
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl - Novaplus
Fentanyl Citrate
Fentanyl [INN:BAN]
Fentanyl citrate
Fentanyl-100
 
Fentanyl-12
Fentanyl-25
Fentanyl-50
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
HSDB 3329
IONSYS
JNS020QD
L001275
LS-124439
Lazanda
Matrifen
MolPort-003-847-369
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
NCGC00168252-01
Nasalfent
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
Subsys
UNII-UF599785JZ
fentanyl
4
FluorouracilapprovedPhase 3, Phase 2, Phase 1, Phase 0193751-21-83385
Synonyms:
1-fluoro-1h-pyrimidine-2,4-dione
1004-03-1
1upf
2,4-Dihydroxy-5-fluoropyrimidine
2,4-Dioxo-5-fluoropryimidine
2,4-Dioxo-5-fluoropyrimidine
47576_FLUKA
4921-97-5
5 FU Lederle
5 FU medac
5 Fluorouracil
5 Fluorouracil biosyn
5 HU Hexal
5-FU
5-FU (TN)
5-FU Lederle
5-FU medac
5-Faracil
5-Fluor-2,4(1H,3H)-pyrimidindion
5-Fluor-2,4(1H,3H)-pyrimidindion [Czech]
5-Fluor-2,4-dihydroxypyrimidin
5-Fluor-2,4-dihydroxypyrimidin [Czech]
5-Fluor-2,4-pyrimidindiol
5-Fluor-2,4-pyrimidindiol [Czech]
5-Fluoracil
5-Fluoracil [German]
5-Fluoracyl
5-Fluoro-2,4(1H,3H)-pyrimidinedione
5-Fluoro-2,4-pyrimidinedione
5-Fluoropyrimidin-2,4-diol
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluoruracil
5-Fluoruracil [German]
5-Fluracil
5-Ftouracyl
5-HU Hexal
5-fluoro uracil
5-fluoro-1H-pyrimidine-2,4-dione
5-fluoropyrimidine-2,4(1H,3H)-dione
5-fluorouracil
51-21-8
5FU
79108-01-3
AC-11201
AC1L1FTE
AC1Q4N2X
AI3-25297
AKOS000119162
AKOS003237897
AccuSite
Actino-Hermal
Adrucil
Adrucil (TN)
Allergan Brand of Fluorouracil
Arumel
BB_NC-0576
BSPBio_002048
C07649
C4H3FN2O2
CCRIS 2582
CHEBI:46345
CHEMBL185
CID3385
CPD0-1327
CPD000038082
CSP Brand of Fluorouracil
Carac
Carac (TN)
Carzonal
Cinco FU
Cytosafe
D005472
D00584
DB00544
Dakota Brand of Fluorouracil
Dakota, Fluorouracile
Dermatech Brand of Fluorouracil
Dermik Brand of Fluorouracil
DivK1c_000054
EINECS 200-085-6
EU-0100536
Effluderm
Effluderm (free base)
Efudex
Efudix
Efurix
F 6627
F0151
F6627_SIGMA
F8423_SIGMA
FT-0082524
FU
Ferrer Brand of Fluorouracil
Fiverocil
Fluoro Uracil
Fluoro Uracile ICN
Fluoro-Uracile ICN
Fluoro-uracile
Fluoro-uracilo
Fluoroblastin
Fluoroplex
Fluoroplex (TN)
Fluorouracil
Fluorouracil (JP15/USP/INN)
Fluorouracil GRY
Fluorouracil Mononitrate
Fluorouracil Monopotassium Salt
Fluorouracil Monosodium Salt
Fluorouracil Potassium Salt
Fluorouracil Teva Brand
Fluorouracil [USAN:INN:BAN:JAN]
 
Fluorouracil-GRY
Fluorouracile
Fluorouracile Dakota
Fluorouracile [DCIT]
Fluorouracilo
Fluorouracilo Ferrer Far
Fluorouracilo [INN-Spanish]
Fluorouracilum
Fluorouracilum [INN-Latin]
Fluoruracil
Fluouracil
Flurablastin
Fluracedyl
Fluracil
Fluracilum
Fluri
Fluril
Fluro Uracil
Fluroblastin
Flurodex
Flurouracil
Flurox
Ftoruracil
Gry Brand of Fluorouracil
HMS1920O18
HMS2090I04
HMS2091F19
HMS500C16
HSDB 3228
Haemato Brand of Fluorouracil
Haemato fu
Haemato-fu
Hexal Brand of Fluorouracil
I07-0022
ICN Brand of Fluorouracil
IDI1_000054
IN1335
KBio1_000054
KBio2_001321
KBio2_003889
KBio2_006457
KBio3_001268
KBioGR_001253
KBioSS_001321
Kecimeton
LS-153
Lopac-F-6627
Lopac0_000536
MLS000069498
MLS002415705
MolPort-000-156-102
MolPort-003-990-447
MolPort-004-758-143
MolPort-004-758-144
MolPort-005-861-486
NCGC00015442-01
NCGC00015442-03
NCGC00015442-10
NCGC00091349-01
NCGC00091349-02
NCGC00091349-03
NCGC00091349-04
NCGC00091349-05
NCGC00091349-07
NCGC00091349-08
NCI60_001652
NINDS_000054
NSC 19893
NSC-19893
NSC19893
Neocorp Brand of Fluorouracil
Neofluor
Onkofluor
Onkoworks Brand of Fluorouracil
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Riemser Brand of Fluorouracil
Ro 2-9757
Ro-2-9757
Roche Brand of Fluorouracil
S1209_Selleck
SAM002264615
SMR000038082
SPBio_000291
SPECTRUM1500305
STK297802
Spectrum2_000076
Spectrum3_000434
Spectrum4_000557
Spectrum5_000718
Spectrum_000841
T5233394
TL8006093
Teva Brand of Fluorouracil
Timazin
U 8953
U-8953
UNII-U3P01618RT
UPCMLD-DP130
UPCMLD-DP130:001
URF
Ulup
WLN: T6MVMVJ EF
ZINC00897110
biosyn Brand of Fluorouracil
fluorouracil
inhibits thymilidate synthetase
medac Brand of Fluorouracil
nchembio.90-comp3
nchembio809-comp6
ribosepharm Brand of Fluorouracil
tetratogen
5
CisplatinapprovedPhase 3, Phase 2243715663-27-184093, 441203, 2767
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
CDDP
CHEBI:35852
CID441203
CPD0-1392
CPDC
CPDD
Carboquone
Cis Pt II
Cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
Cismaplat
Cisplatin
Cisplatine
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
DB00515
DDP
DDPT
Diamminedichloroplatinum
 
EU-0100918
Lederplatin
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinol-aq
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
Trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
cis-DDP
cis-Diamminedichloroplatinum
cis-Dichlorodiammineplatinum(II)
cis-[PtCl2(NH3)2]
cis-diamminedichloridoplatinum(II)
cis-diamminedichloroplatinum(II)
nchembio773-comp1
trans-diamminedichloridoplatinum(II)
6pancreatic polypeptidePhase 3, Phase 120
7MitomycinsPhase 3, Phase 2, Phase 1, Phase 0208
8
CarboplatinapprovedPhase 2, Phase 1181241575-94-410339178, 498142, 38904, 38904, 498142
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
9
PaclitaxelapprovedPhase 2, Phase 1250533069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
10
Capecitabineapproved, investigationalPhase 2, Phase 11179154361-50-960953
Synonyms:
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
154361-50-9
158798-73-3
5'-Deoxy-5-fluoro-N-((pentyloxy)carbonyl)cytidine
5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]cytidine
AC1L1U83
AC1Q4KU8
Ambap154361-50-9
C110904
C12650
C15H22FN3O6
CAPE
CAPECITABINE
CHEBI:31348
CHEMBL1773
CID60953
Capecitabin
Capecitabina
Capecitabine
Capecitabine (JAN/USAN/INN)
Capecitabine [USAN]
Capecitabinum
Capecitibine
Capiibine
Carbamic acid, (1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-, pentyl ester
Caxeta
 
D01223
DB01101
FT-0082472
HSDB 7656
LS-59070
MolPort-005-938-254
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
R-340
R340
RG-340
Ro 09-1978
Ro 09-1978/000
Ro-09-1978
Ro-09-1978/000
S1156_Selleck
UNII-6804DJ8Z9U
Xabine
Xeloda
Xeloda (TN)
Xeloda, Captabin, Capecitabine
ZINC03806413
capecitabina
capecitabine
capecitabinum
pentyl N-[1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-methyloxolan-2-yl]-5-fluoro-2-oxopyrimidin-4-yl]carbamate
11
SuccinylcholineapprovedPhase 2123306-40-15314
Synonyms:
2,2'-[(1,4-DIOXOBUTANE-1,4-DIYL)BIS(OXY)]BIS(N,N,N-TRIMETHYLETHANAMINIUM)
2,2'-[(1,4-DIOXOBUTANE-1,4-diyl)bis(oxy)]bis(N,N,N-trimethylethanaminium)
2ha2
2ha6
306-40-1
4-04-00-01451 (Beilstein Handbook Reference)
541-19-5 (diiodide)
55-94-7 (dibromide)
71-27-2 (dichloride)
AC1L1K2T
Anectine
BRN 1805311
C07546
C14H30N2O4
CHEBI:45652
CHEMBL703
CID5314
Choline, succinate (2:1) (ester)
Choline, succinate (ester)
DB00202
Diacetylcholine
Dicholine succinate
Ditilin
Ditiline
HMS2090P14
HSDB 3254
InChI=1/C14H30N2O4/c1-15(2,3)9-11-19-13(17)7-8-14(18)20-12-10-16(4,5)6/h7-12H2,1-6H3/q+2
L000926
LS-53328
Listenon
 
Lopac-S-8251
Lopac0_001080
Lysthenon
MolPort-002-964-486
NCGC00015971-01
NCGC00015971-03
NCGC00162336-01
Quelicin
Quelicin Preservative Free
SCK
ST50437287
STK177290
Scoline
Succicuran
Succinic acid, diester with choline
Succinic acid, diester with choline chloride
Succinocholine
Succinoylcholine
Succinyl choline
Succinylbischoline
Succinylcholine
Succinylcholine Chloride
Succinyldicholine
Sucostrin
Suxamethonium
Suxamethonium chloride
UNII-J2R869A8YF
ZINC01530820
succinylcholine
succinyldicholine
trimethyl-[2-[4-oxo-4-(2-trimethylazaniumylethoxy)butanoyl]oxyethyl]azanium diio
trimethyl-[2-[4-oxo-4-[2-(trimethylazaniumyl)ethoxy]butanoyl]oxyethyl]azanium
12
Palonosetronapproved, investigationalPhase 276119904-90-4148211
Synonyms:
(3aR)-2-[(3S)-1-azabicyclo[2.2.2]octan-3-yl]-3a,4,5,6-tetrahydro-3H-benzo[de]isoquinolin-1-one
(3aS)-2,3,3a,4,5,6-hexahydro-2-[(3S)-3-quinuclidinyl]-1H-benz[de]isoquinolin-1-one
(3aS)-2-[(3S)-1-azabicyclo[2.2.2]oct-3-yl]-2,3,3a, 4,5,6-hexahydro-1H-benz[de]isoquinolin-1-one
(S-(R*,R*))-2-(1-Azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz(de)isoquinolin-1-one
135729-56-5
135729-61-2
2-(1-Azabicyclo(2.2.2)oct-3-yl)-2,3,3a,4,5,6-hexahydro-1H-benz(de)isoquinolin-1-one
2-Qhbiqo
AC1L3WNN
Aloxi
CID148211
DB00377
LS-186967
LS-187778
NCGC00166415-01
NCGC00166415-02
 
Onicit
Palonosetron
Palonosetron Hydrochloride
Palonosetron [INN]
Palonosetronum
Palonosetrón
Palonosétron
RS 25233-197
RS 25233-198
RS 25259-197
RS 25259-198
RS-25233-197
RS-25233-198
RS-25259-197
RS-25259-198
SID50111798
UNII-5D06587D6R
13
Docetaxelapproved, investigational, Approved May 1996Phase 2, Phase 11792114977-28-5148124, 9877265
Synonyms:
(2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]amino]-a-hydroxybenzenepropanoate
(2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate
01885_FLUKA
114977-28-5
4-(Acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
AC-383
AC1L3WHJ
ANX-514
BIND-014
C11231
CHEBI:4672
CHEMBL92
CID148124
D07866
DB01248
Docefrez
Docetaxel
Docetaxel (INN)
Docetaxel anhydrous
Docetaxel, Trihydrate
EmDOC
 
HMS2089K08
InChI=1/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,5
MolPort-003-847-005
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-Debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel
N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol
N-debenzoyl-N-Boc-10-deacetyl taxol
NSC-628503
PSMA-targeted docetaxel nanoparticle
RP-56976
SDP-014
TXL
Taxotere
Taxotere (TN)
Taxotere(R)
XRP-6976L
docetaxel
docetaxel 114977-28-5
nchembio.188-comp8
nchembio.2007.34-comp7
nchembio.573-comp11
nchembio853-comp8
14taxanePhase 2313
15
SerotoninPhase 2285350-67-95202
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
 
5-Hydroxy-tryptamine
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
Antemovis
DS substance
Enteramin
Enteramine
16
CetuximabapprovedPhase 1696205923-56-456842117, 2333
Synonyms:
205923-56-4
Anti EGFR
Cetuximab
Cetuximab (USAN/INN)
Cetuximab (genetical recombination)
 
Cetuximab (genetical recombination) (JAN)
D03455
Erbitux
Erbitux (TN)
IMC-C225
cetuximab
17
Irinotecanapproved, investigationalPhase 1101397682-44-5, 100286-90-660838
Synonyms:
(+)-Irinotecan
(4S)-4,11-DIETHYL-4-HYDROXY-3,14-DIOXO-3,4,12,14-TETRAHYDRO-1H-PYRANO[3',4':6,7]INDOLIZINO[1,2-B]QUINOLIN-9-YL 1,4'-BIPIPERIDINE-1'-CARBOXYLATE
(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-4,12-dihydro-1H-pyrano[3,4-f]quinolino[2,3-a]indolizin-9-yl 4-piperidylpiperidinecarboxylate
1u65
97682-44-5
AC-7469
AC1L1U0Z
AC1Q6PGI
BRD-K08547377-003-02-4
BSPBio_002346
Bio-0054
Biotecan
Biotecan (TN)
C16641
C33H38N4O6
CHEBI:105985
CHEMBL481
CID60838
CP0
Campothecin-11
Campto
Camptosar
 
Camptosar, Campto, CPT-11, Irinotecan
Camptothecin-11
D08086
DB00762
FT-0083650
HSDB 7607
IRINOTECAN HYDROCHLORIDE Trihydrate
IRINOTECAN, CPT-11
Irinotecan
Irinotecan (INN)
Irinotecan Hcl
Irinotecan Hydrochloride
Irinotecan Hydrochloride Trihydrate
Irinotecan [INN:BAN]
Irinotecan hydrochloride
Irinotecanum
Irinotecanum [INN-Latin]
LS-44589
NCI60_005051
NSC728073
S1198_Selleck
TL8006026
UNII-7673326042
irinotecan
18
Erlotinibapproved, investigationalPhase 1759183321-74-6176870, 176871
Synonyms:
183321-74-6
4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline
774
AB1004620
AC-399
AC1L42EI
AKOS000282911
AQ4
BCB03_000783
C400278
CHEBI:114785
CHEMBL553
CID176870
CP 358,774
CP-258
CP-358,774
CP-358774
DB00530
EN002711
Erlotinib
Erlotinib Base
Erlotinib Hydrochloride
Erlotinib(Tarceva)
Erlotinib, OS-774
 
Erlotinin
FT-0083688
HMS2089F05
I01-1241
K00241
Kinome_3317
LS-184395
MolPort-003-847-084
N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine
N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
NCGC00164574-01
NSC 718781
OSI 744
OSI-774
R 1415
SR-05000001460
SR-05000001460-2
STK623143
Tarceva
UNII-J4T82NDH7E
ZINC01546066
[6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE
[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
erlotinib
n-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine
nchembio866-comp3
19
Trastuzumabapproved, investigationalPhase 1688180288-69-19903
Synonyms:
180288-69-1
Anti HER2
Anti-erbB2 Monoclonal Antibody
D03257
HER2 Monoclonal Antibody
Herceptin
 
Herceptin (TN)
Ig gamma-1 chain C region
Trastuzumab
Trastuzumab (INN)
Trastuzumab (genetical recombination)
Trastuzumab (genetical recombination) (JAN)
trastuzumab
20
leucovorinapprovedPhase 19221492-18-854575
Synonyms:
(6S)-5-Formyl-5,6,7,8-tetrahydrofolic acid
(6S)-Folinic acid
(6S)-Leucovorin
(S)-Leucovorin
Calcium citrovorum factor
Calcium folinate
Citrovorum factor
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid-SF
Fusilev
 
L-Folinic acid
L-leucovorin
Leucal
Leucovorin
Leucovorin Calcium
Leucovorin calcium
Leucovorin folinic acid
Leucovorin sodium
Leukovorin
Levofolene
Levofolinic acid
Levoleucovorin
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamic acid
Wellcovorin
21
CamptothecinexperimentalPhase 11967689-03-424360
Synonyms:
(+)-camptothecin
(+)-camptothecine
(s)-(+)-camptothecin
 
(s)-camptothecin
20(S)-Camptothecin
21,22-Secocamptothecin-21-oic acid lactone
Camptothecine
D-camptothecin
22
7-hydroxystaurosporineexperimentalPhase 122112953-11-472271, 46936262
Synonyms:
(5s,6r,7r,9r,16r)-16-hydroxy-6-methoxy-5-methyl-7-(methylamino)-6,7,8,9,15,16-hexahydro-5h,14h-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-14-one
112953-11-4
1okz
7-Hydroxystaurosporine
7-hydroxystaurosporine (UCN-01)
98290-92-7
AC1Q6PB4
AR-1A6540
C28H26N4O4
CHEBI:46153
CHEMBL1236539
CPD-11911
 
KRX-0601
KST-1A9223
KW-2401
LS-64044
NCI60_012974
NSC 638850
NSC-638850
NSC638850
UCN
UCN-01
UCN-02
UCN01
Ucn 01
23StaurosporineexperimentalPhase 11862996-74-144120114
24Calcium, DietaryPhase 13529
25Interleukin-12Phase 1123
26
EntinostatPhase 133
Synonyms:
Entinostat
 
MS-275
SNDX-275
27
tipifarnibPhase 179
Synonyms:
IND58359
 
Zarnestra
tipifarnib
28Interferon-betaPhase 1244
29LevoleucovorinPhase 1659
30TempolPhase 132226-96-2
31Folinic AcidNutraceuticalPhase 12498
32
Gabapentinapproved, investigational25460142-96-33446
Synonyms:
1-(Aminomethyl)-cyclohexaneacetic acid
1-(Aminomethyl)cyclohexaneacetic acid
2-[1-(aminomethyl)cyclohexyl]acetic acid
60142-96-3
AC-1485
AC1L1FYE
AC1Q53PH
AKOS000280865
Aclonium
Apo-Gabapentin
Apotex brand of gabapentin
Aventis brand of gabapentin
BB_SC-1512
BIDD:GT0656
BPBio1_000993
BRN 2359739
BSPBio_000901
C040029
C9H17NO2
CAS-60142-96-3
CCRIS 7210
CHEBI:188316
CHEBI:42797
CHEMBL940
CI 945
CI-945
CID3446
D00332
DB00996
DDS-2003
DM-1796
DM-5689
EINECS 262-076-3
EU-0100582
G-154
G0318
G154_SIGMA
GBN
GOE 2450
Gabapen
Gabapentin
Gabapentin (JAN/USAN/INN)
Gabapentin GR
Gabapentin Hexal
Gabapentin Kit
Gabapentin Stada
Gabapentin [USAN:INN:BAN]
Gabapentin-ratiopharm
Gabapentina
Gabapentine
Gabapentine [INN-French]
Gabapentino
Gabapentino [INN-Spanish]
Gabapentino [Spanish]
Gabapentinum
 
Gabapentinum [INN-Latin]
Gabapetin
Go 3450
Goe-3450
Gralise
Gralise Starter Pack
HMS1570N03
HMS2089J03
HSDB 7364
Hexal brand of gabapentin
I06-0677
L000733
LS-7194
Lopac-G-154
Lopac0_000582
MLS000069358
MolPort-000-883-862
NCGC00015466-01
NCGC00015466-02
NCGC00015466-06
NCGC00015466-09
NCGC00016891-01
NCGC00021545-02
NCGC00021545-04
NCGC00021545-05
NSC742194
Neurontin
Neurontin (TN)
Novo-Gabapentin
Novo-Gabapentine
Novopharm brand of gabapentin
PMS-Gabapentin
Parke Davis brand of gabapentin
Pfizer brand of gabapentin
Pharmascience brand of gabapentin
Prestwick0_000861
Prestwick1_000861
Prestwick2_000861
Prestwick3_000861
Prestwick_151
S2133_Selleck
SMR000058311
SPBio_002822
STK598009
Serada
Stadapharm brand of gabapentin
TL8003814
Tocris-0806
UNII-6CW7F3G59X
Vultin
Warner-Lambert brand of gabapentin
[1-(AMINOMETHYL)CYCLOHEXYL]ACETIC ACID
gabapentin
gabapentin (Neurontin)
gabapentina
gabapentinium
ratiopharm brand of gabapentin

Interventional clinical trials:

(show all 50)
idNameStatusNCT IDPhase
1Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal CancerRecruitingNCT00274885Phase 4
2Anal Dysplasia Study of Men Who Have Sex With Men Living With HIVWithdrawnNCT01663558Phase 4
3Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal CancerCompletedNCT00003596Phase 3
4Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer PainCompletedNCT00538850Phase 3
5Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal CancerActive, not recruitingNCT00003652Phase 3
6A Study of Substitution of 5-FU (Fluorouracil) by Capecitabine in Scheme of Chemo-radiotherapy in Patients With Squamous Cell Carcinoma of the Anal Canal.CompletedNCT01941966Phase 2
7Capecitabine, Oxaliplatin, and Radiation Therapy in Treating Patients With Stage II or Stage III Anal CancerCompletedNCT00093379Phase 2
8Clinical and Biological Interest of Taxanes in Advanced Squamous Cell Anal CarcinomaRecruitingNCT02402842Phase 2
9Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV InfectionRecruitingNCT02437851Phase 2
10Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal CanalRecruitingNCT01843452Phase 2
11A Phase II Study to Assess Acute Toxicity and Quality of Life of Patients With Carcinoma of the Anal Canal Receiving Chemotherapy and Radiation Using Helical TomotherapyRecruitingNCT00754078Phase 2
12Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver MetastasesRecruitingNCT02185443Phase 2
13Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)RecruitingNCT02628067Phase 2
14Nivolumab in Treating Patients With Refractory Metastatic Squamous Cell Carcinoma of the Anal CanalActive, not recruitingNCT02314169Phase 2
15Vectibix for the Treatment of Anal CancerActive, not recruitingNCT01285778Phase 2
16Intensity-Modulated Radiation Therapy, Fluorouracil, and Mitomycin C in Treating Patients With Invasive Anal CancerActive, not recruitingNCT00423293Phase 2
17Phase 2 Study of ADXS11-001 in Subjects With Anal Cancer or Cancer of the RectumActive, not recruitingNCT02399813Phase 1, Phase 2
18Cisplatin and Fluorouracil Compared With Carboplatin and Paclitaxel in Treating Patients With Inoperable Locally Recurrent or Metastatic Anal CancerNot yet recruitingNCT02560298Phase 2
19Nimotuzumab With Radiotherapy in the Treatment of Anal Canal CancersTerminatedNCT01382745Phase 2
20Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal CancerTerminatedNCT00903396Phase 2
21Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
227-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1
23Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerCompletedNCT00397384Phase 1
24Interleukin-12 in Treating Patients With Cancer in the AbdomenCompletedNCT00003046Phase 1
25Oxaliplatin Plus Irinotecan in Treating Patients With Metastatic Gastrointestinal CancerCompletedNCT00003427Phase 1
26Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic CancerCompletedNCT00005842Phase 1
27MS-275 in Treating Patients With Advanced Solid Tumors or LymphomaCompletedNCT00020579Phase 1
28Thalidomide and Docetaxel in Treating Patients With Advanced CancerCompletedNCT00049296Phase 1
29Aminocamptothecin in Treating Patients With Advanced Cancer of the Peritoneal CavityCompletedNCT00003548Phase 1
30Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal CancerCompletedNCT00003439Phase 1
31Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal CancerActive, not recruitingNCT00654160Phase 1
32Irinotecan and Capecitabine in Treating Patients With Solid TumorsActive, not recruitingNCT00003867Phase 1
33Intrapleural BG00001 in Treating Patients With Malignant Pleural Mesothelioma or Malignant Pleural EffusionsActive, not recruitingNCT00066404Phase 1
34Topical MTS-01 for Dermatitis During Radiation and Chemotherapy for Anal CancerTerminatedNCT01324141Phase 1
35Cancer in Patients With Gabapentin (GPRD)CompletedNCT01236053
36A Trial of Radiofrequency Ablation for Anal Intraepithelial Neopplasia Using the HALO Ablation SystemCompletedNCT01970787
37B-Receptor Signaling in CardiomyopathyCompletedNCT01135849
38Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer PatientsCompletedNCT00253383
39Medico-economic Evaluation Comparing Intensity-Modulated Radiation Therapy (IMRT) Performed by Helical Tomotherapy and Dynamic Arc Therapy in Prostate, Cervical and Anal Canal CancersRecruitingNCT01325961
40Evaluation of Immune Response Against Human Papillomavirus (HPV)in Patients With Metastatic Cancer of the Anal CanalRecruitingNCT01845779
41Chemoradiation and Endothelial Progenitor Cells in Colorectal CancerRecruitingNCT00325871
42Concurrent Chemoradiation + 5-FU + Mitomycin-C in Anal CarcinomaRecruitingNCT01858025Phase 0
43Multimodal Monitoring of Radiotherapy Response in Squamous Cell CancerRecruitingNCT02379039
44Health-Related Symptom Questionnaires in Measuring Quality of Life in HIV-Infected Participants Treated or Monitored for Anal LesionsRecruitingNCT02418494
45Extralevator Versus Standard Abdominoperineal Resection For Rectal AdenocarcinomaRecruitingNCT01702116
46Permission to Collect Blood Over Time for ResearchRecruitingNCT00767234
47Cancer Research Repository for Individuals With Cancer Diagnosis and High Risk Individuals.RecruitingNCT02012699
48A Safety and Tolerability of Circumferential Anal Canal Radiofrequency Ablation For Anal Intraepithelial NeoplasiaActive, not recruitingNCT02189161
49Quality of Life in Patients Undergoing Radiation Therapy for Primary Lung Cancer, Head and Neck Cancer, or Gastrointestinal CancerActive, not recruitingNCT00836992
50The HPV-SAVE Study Team: HPV Screening and Vaccine Evaluation in Men Who Have Sex With MenEnrolling by invitationNCT02503111

Search NIH Clinical Center for Anal Canal Carcinoma

Genetic Tests for Anal Canal Carcinoma

About this section

Anatomical Context for Anal Canal Carcinoma

About this section

MalaCards organs/tissues related to Anal Canal Carcinoma:

33
Prostate, Skin

Animal Models for Anal Canal Carcinoma or affiliated genes

About this section

Publications for Anal Canal Carcinoma

About this section

Articles related to Anal Canal Carcinoma:

(show top 50)    (show all 65)
idTitleAuthorsYear
1
Locally advanced anal canal carcinoma: is the addition of cetuximab the answer? (25976929)
2015
2
Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. (24243447)
2014
3
Management of persistent anal canal carcinoma after combined-modality therapy: a clinical review. (24472223)
2014
4
Benefit of MRI scanning in the pretreatment assessment of anal canal carcinoma. (24674573)
2013
5
Changing patterns of anal canal carcinoma in the United States. (23509304)
2013
6
Phase 1 study of cetuximab in combination with 5-fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma. (23674135)
2013
7
Light microscopic observation on phagocytosis of Candida spp. blastospores by Trichomonas vaginalis in a patient with anal canal carcinoma. (21395883)
2012
8
Chemotherapy in the treatment of anal canal carcinoma. (22658644)
2012
9
Endobronchial metastases of anal canal carcinoma. (22055765)
2012
10
Twenty-year experience in the management of squamous cell anal canal carcinoma with interstitial brachytherapy. (21775274)
2011
11
Results of salvage abdominoperineal resection after failed chemoradiation therapy for epidermoid anal canal carcinoma: Retrospective analysis at a single institution. (22331724)
2011
12
Anal canal carcinoma treatment results: the experience of a single institution. (21403412)
2011
13
Mitomycin-C- or cisplatin-based chemoradiotherapy for anal canal carcinoma: long-term results. (20472349)
2011
14
Quality of life and tumor control after short split-course chemoradiation for anal canal carcinoma. (20492729)
2010
15
Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. (19399614)
2010
16
Conformal external beam radiotherapy in the treatment of anal canal carcinoma: a retrospective study of a genital organ sparing technique. (19695047)
2009
17
Induction therapy for poor-prognosis anal canal carcinoma: a phase II study of the cancer and Leukemia Group B (CALGB 9281). (18490648)
2008
18
Radiochemotherapy of locally advanced anal canal carcinoma: prospective assessment of early impact on the quality of life (randomized trial ACCORD 03). (18191265)
2008
19
Radiotherapy and chemotherapy in the conservative treatment of anal canal carcinoma. (18505075)
2008
20
Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans. (18005443)
2007
21
The aspects of angiogenesis in anal canal carcinomas compared with that in colorectal carcinomas. (18060184)
2007
22
Anal canal carcinoma with Pagetoid spread: report of a case. (16794808)
2006
23
Treatment of squamous cell anal canal carcinoma (SCACC) with pulsed dose rate brachytherapy: a retrospective study. (16631268)
2006
24
Epidermal growth factor receptor expression in anal canal carcinoma. (15923158)
2005
25
Anal canal carcinoma: early-stage tumors < or =10 mm (T1 or Tis): therapeutic options and original pattern of local failure after radiotherapy. (15890590)
2005
26
Radiochemotherapy in the conservative treatment of anal canal carcinoma: retrospective analysis of results and radiation dose effectiveness. (15752894)
2005
27
Contribution of conformal therapy in the treatment of anal canal carcinoma with combined chemotherapy and radiotherapy: results of a phase II study. (12788191)
2003
28
Analysis of a follow-up program for anal canal carcinoma. (11484975)
2001
29
Prognostic impact of CD31 antigen expression in anal canal carcinoma. (11677963)
2001
30
Intracavitary afterloading boost in anal canal carcinoma. Results, function and quality of life. (11398611)
2001
31
The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy. (11395235)
2001
32
nm23-H1 protein expression in anal canal carcinoma: does it correlate with prognosis? (10914829)
2000
33
An unusual late radiotherapy-related complication requiring surgery in anal canal carcinoma. (10914830)
2000
34
Treatment of squamous cell anal canal carcinoma with pulsed dose rate brachytherapy. Feasibility study of a French cooperative group. (10435803)
1999
35
Correlation between nm23-H1 overexpression and clinicopathological variables in human anal canal carcinoma. (10523705)
1999
36
Role of a DT-diaphorase mutation in the response of anal canal carcinoma to radiation, 5-fluorouracil, and mitomycin C. (9788412)
1998
37
The prevalence of p53 immunoreactivity in anal canal carcinoma. (9769387)
1998
38
Role of dose intensity in conservative treatment of anal canal carcinoma. Report of 35 cases. (9778618)
1998
39
Sphincter preservation with chemoradiation in anal canal carcinoma: abdominoperineal resection in selected cases? (9559628)
1998
40
Epidermoid anal canal carcinoma metastatic to the skin. A clinical mimic of prostate adenocarcinoma metastases. (7962940)
1994
41
Late recurrence following treatment of anal canal carcinoma. (1712526)
1991
42
Feasibility of non-surgical definitive management of anal canal carcinoma. (3384732)
1988
43
Our experience of conservative treatment of anal canal carcinoma combining external irradiation and interstitial implant: 32 cases treated between 1973 and 1982. (3338946)
1988
44
Feasibility of non-surgical definitive management of anal canal carcinoma. (3104242)
1987
45
Recurrent deletions of chromosomes 11q and 3p in anal canal carcinoma. (3570551)
1987
46
Treatment of anal canal carcinoma. (3919927)
1985
47
Results and toxicity of the treatment of anal canal carcinoma by radiation therapy or radiation therapy and chemotherapy. (6435851)
1984
48
Radiation therapy and chemotherapy in the treatment of primary anal canal carcinoma. (6831854)
1983
49
Definitive treatment of anal-canal carcinoma by means of radiation therapy and chemotherapy. (6813084)
1982
50
Primary radiation therapy in the treatment of anal canal carcinoma. (7172946)
1982

Variations for Anal Canal Carcinoma

About this section

Cosmic variations for Anal Canal Carcinoma:

7 (show top 50)    (show all 5908)
id Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Conf
112193TP53prostate,NS,carcinoma,adenocarcinoma3
211306TP53lung,NS,carcinoma,adenocarcinoma3
344945TP53lung,NS,carcinoma,adenocarcinoma3
410769TP53prostate,NS,carcinoma,adenocarcinoma3
511450TP53lung,NS,carcinoma,adenocarcinoma3
611224TP53prostate,NS,carcinoma,adenocarcinoma3
743896TP53lung,NS,carcinoma,adenocarcinoma3
810810TP53lung,NS,carcinoma,adenocarcinoma3
943555TP53lung,NS,carcinoma,adenocarcinoma3
1011451TP53lung,NS,carcinoma,adenocarcinoma3
1143995TP53lung,NS,carcinoma,adenocarcinoma3
1244956TP53lung,NS,carcinoma,adenocarcinoma3
1343592TP53prostate,NS,carcinoma,adenocarcinoma3
1411514TP53lung,NS,carcinoma,adenocarcinoma3
15378685TP53lung,NS,carcinoma,adenocarcinoma3
1644102TP53lung,NS,carcinoma,adenocarcinoma3
17674226TP53lung,NS,carcinoma,adenocarcinoma3
1845822TP53lung,NS,carcinoma,adenocarcinoma3
1945794TP53prostate,NS,carcinoma,adenocarcinoma3
2044571TP53lung,NS,carcinoma,adenocarcinoma3
2110726TP53lung,NS,carcinoma,adenocarcinoma3
2244525TP53lung,NS,carcinoma,adenocarcinoma3
2344776TP53lung,NS,carcinoma,adenocarcinoma3
2443973TP53lung,NS,carcinoma,adenocarcinoma3
2510659TP53lung,NS,carcinoma,adenocarcinoma3
2610768TP53lung,NS,carcinoma,adenocarcinoma3
2743989TP53lung,NS,carcinoma,adenocarcinoma3
2811059TP53lung,NS,carcinoma,adenocarcinoma3
2910651TP53lung,NS,carcinoma,adenocarcinoma3
3012732TP53lung,NS,carcinoma,adenocarcinoma3
3143966TP53lung,NS,carcinoma,adenocarcinoma3
3244801TP53lung,NS,carcinoma,adenocarcinoma3
3343878TP53lung,NS,carcinoma,adenocarcinoma3
3410743TP53lung,NS,carcinoma,adenocarcinoma3
3510912TP53lung,NS,carcinoma,adenocarcinoma3
3648817TP53lung,NS,carcinoma,adenocarcinoma3
3743708TP53lung,NS,carcinoma,adenocarcinoma3
3843836TP53lung,NS,carcinoma,adenocarcinoma3
3943582TP53lung,NS,carcinoma,adenocarcinoma3
4043687TP53lung,NS,carcinoma,adenocarcinoma3
41144150TP53lung,NS,carcinoma,adenocarcinoma3
4246057TP53lung,NS,carcinoma,adenocarcinoma3
4310834TP53lung,NS,carcinoma,adenocarcinoma3
4411123TP53lung,NS,carcinoma,adenocarcinoma3
45144153TP53lung,NS,carcinoma,adenocarcinoma3
4645306TP53prostate,NS,carcinoma,adenocarcinoma3
4743692TP53lung,NS,carcinoma,adenocarcinoma3
48145025TP53lung,NS,carcinoma,adenocarcinoma3
4910647TP53lung,NS,carcinoma,adenocarcinoma3
5010709TP53lung,NS,carcinoma,adenocarcinoma3

Expression for genes affiliated with Anal Canal Carcinoma

About this section
Search GEO for disease gene expression data for Anal Canal Carcinoma.

Pathways for genes affiliated with Anal Canal Carcinoma

About this section

GO Terms for genes affiliated with Anal Canal Carcinoma

About this section

Cellular components related to Anal Canal Carcinoma according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1intermediate filamentGO:00058829.3KRT13, KRT20

Sources for Anal Canal Carcinoma

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet